Amgen files reply for judgment in Regeneron's US antitrust case over cholesterol drug
MLex Summary: Amgen filed a reply in support of its motion for a judgment in its favor after a jury awarded Regeneron damages in an antitrust suit over cholesterol-reducing medication, saying...To view the full article, register now.
Already a subscriber? Click here to view full article